EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 34 / Numéro 1 (Janvier 2018) Med Sci (Paris), 34 1 (2018) 72-78 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 34, Numéro 1, Janvier 2018
Page(s) 72 - 78
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20183401016
Publié en ligne 31 janvier 2018
  1. Lahaie YM, Watier H. Contribution of physiologists to the identification of the humoral component of immunity in the 19th century. MAbs 2017; 9 : 774-80. [CrossRef] [PubMed] [Google Scholar]
  2. Von Behring E, Kitasato S. The mechanism of diphtheria immunity and tetanus immunity in animals (1890). Mol Immunol 1991; 1317 : 1319-20. [Google Scholar]
  3. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254 : 1643-7. [Google Scholar]
  4. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94 : 1914-8. [CrossRef] [Google Scholar]
  5. Lee YT, Sheikh KM, Quismorio FP Jr, Friou GJ. Circulating anti-tumor and autoantibodies in breast carcinoma: relationship to stage and prognosis. Breast Cancer Res Treat 1985; 6 : 57-65. [CrossRef] [PubMed] [Google Scholar]
  6. Andreu P, Johansson M, Affara NI, et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010; 17 : 121-34. [CrossRef] [PubMed] [Google Scholar]
  7. Karagiannis P, Gilbert AE, Josephs DH, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013; 123 : 1457-74. [CrossRef] [PubMed] [Google Scholar]
  8. Qin Z, Richter G, Schuler T, et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998; 4 : 627-30. [CrossRef] [PubMed] [Google Scholar]
  9. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7 : 411-23. [CrossRef] [PubMed] [Google Scholar]
  10. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol 2000; 12 : 597-605. [CrossRef] [PubMed] [Google Scholar]
  11. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity 2015; 42 : 607-12. [CrossRef] [PubMed] [Google Scholar]
  12. Shalapour S, Font-Burgada J, Di Caro G, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015; 521 : 94-8. [CrossRef] [PubMed] [Google Scholar]
  13. Watt V, Ronchese F, Ritchie D. Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J Immunother 2007; 30 : 323-32. [CrossRef] [PubMed] [Google Scholar]
  14. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005; 238 : 67-75. [Google Scholar]
  15. Germain C, Gnjatic S, Tamzalit F, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014; 189 : 832-44. [CrossRef] [PubMed] [Google Scholar]
  16. Shi JY, Gao Q, Wang ZC, et al. Margin-infiltrating CD20+ B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma. Clin Cancer Res 2013; 19 : 5994-6005. [CrossRef] [PubMed] [Google Scholar]
  17. Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells: Working together to promote patient survival. Oncoimmunology 2012; 1 : 1623-5. [CrossRef] [PubMed] [Google Scholar]
  18. Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic t-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res 2016; 22 : 3005-15. [CrossRef] [PubMed] [Google Scholar]
  19. Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 2017; 66 : 342-51. [CrossRef] [PubMed] [Google Scholar]
  20. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008; 20 : 332-8. [CrossRef] [PubMed] [Google Scholar]
  21. Ritchie DS, Yang J, Hermans IF, Ronchese F. B-lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8+ T-cells. Scand J Immunol 2004; 60 : 543-51. [CrossRef] [PubMed] [Google Scholar]
  22. Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I-and class II-binding peptides. Immunology 2008; 124 : 129-40. [CrossRef] [PubMed] [Google Scholar]
  23. Atanackovic D, Matsuo M, Ritter E, et al. Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods 2003; 278 : 57-66. [CrossRef] [PubMed] [Google Scholar]
  24. Deola S, Panelli MC, Maric D, et al. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J Immunol 2008; 180 : 1362-72. [CrossRef] [PubMed] [Google Scholar]
  25. Lohr M, Edlund K, Botling J, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 2013; 333 : 222-8. [Google Scholar]
  26. Schmidt M, Hellwig B, Hammad S, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012; 18 : 2695-703. [CrossRef] [PubMed] [Google Scholar]
  27. Al-Shibli K, Al-Saad S, Andersen S, et al. The prognostic value of intraepithelial and stromal CD3-, CD117-and CD138-positive cells in non-small cell lung carcinoma. APMIS 2010; 118 : 371-82. [Google Scholar]
  28. Fristedt R, Borg D, Hedner C, et al. Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol 2016; 7 : 848-59. [CrossRef] [PubMed] [Google Scholar]
  29. Mohammed ZM, Going JJ, Edwards J, et al. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 2013; 109 : 1676-84. [CrossRef] [PubMed] [Google Scholar]
  30. Knief J, Reddemann K, Petrova E, et al. High density of tumor-infiltrating B-lymphocytes and plasma cells signifies prolonged overall survival in adenocarcinoma of the esophagogastric junction. Anticancer Res 2016; 36 : 5339-45. [CrossRef] [PubMed] [Google Scholar]
  31. Berntsson J, Nodin B, Eberhard J, et al. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer 2016; 139 : 1129-39. [CrossRef] [PubMed] [Google Scholar]
  32. Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72 : 1070-80. [Google Scholar]
  33. Chen Z, Gerhold-Ay A, Gebhard S, et al. Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One 2012; 7 : e44741. [Google Scholar]
  34. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21 : 938-45. [CrossRef] [PubMed] [Google Scholar]
  35. Lundgren S, Berntsson J, Nodin B, et al. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. J Ovarian Res 2016; 9 : 21. [CrossRef] [PubMed] [Google Scholar]
  36. Pavoni E, Monteriu G, Santapaola D, et al. Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. BMC Biotechnol 2007; 7 : 70. [CrossRef] [PubMed] [Google Scholar]
  37. Mizukami M, Hanagiri T, Shigematsu Y, et al. Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth. Anticancer Res 2006; 26 : 1827-31. [PubMed] [Google Scholar]
  38. Carmi Y, Spitzer MH, Linde IL, et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 2015; 521 : 99-104. [CrossRef] [PubMed] [Google Scholar]
  39. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110 : 71-9. [CrossRef] [PubMed] [Google Scholar]
  40. Lochner M, Ohnmacht C, Presley L, et al. Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells. J Exp Med 2011; 208 : 125-34. [CrossRef] [PubMed] [Google Scholar]
  41. McDonald KG, McDonough JS, Newberry RD. Adaptive immune responses are dispensable for isolated lymphoid follicle formation: antigen-naive, lymphotoxin-sufficient B lymphocytes drive the formation of mature isolated lymphoid follicles. J Immunol 2005; 174 : 5720-8. [CrossRef] [PubMed] [Google Scholar]
  42. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39 : 782-95. [CrossRef] [PubMed] [Google Scholar]
  43. Meshcheryakova A, Tamandl D, Bajna E, et al. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One 2014; 9 : e99008. [CrossRef] [PubMed] [Google Scholar]
  44. Wirsing AM, Rikardsen OG, Steigen SE, et al. Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma. BMC Clin Pathol 2014; 14 : 38. [CrossRef] [PubMed] [Google Scholar]
  45. Shalapour S, Lin XJ, Bastian IN, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 2017; 551 : 340-5. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.